TYRA 430
Alternative Names: TYRA-430Latest Information Update: 05 Jun 2024
At a glance
- Originator Tyra Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer